Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of beta-lactam resistance

J Clin Microbiol. 2008 Jun;46(6):2095-8. doi: 10.1128/JCM.02216-07. Epub 2008 Apr 23.

Abstract

A total of 78 isolates of Pseudomonas aeruginosa grouped according to the phenotype for ceftazidime and imipenem susceptibility/resistance were used to assess the accuracy of the Vitek 2 system in antimicrobial susceptibility testing. Comparisons were made with a MIC gradient test for piperacillin-tazobactam, ceftazidime, aztreonam, imipenem, meropenem, gentamicin, and ciprofloxacin. For the total of 546 isolate-antimicrobial combinations tested, the category agreement was 83.6%, with 2.0, 1.6, and 12.8% very major, major, and minor errors, respectively. Vitek 2 accuracy was influenced differently by the mechanism responsible for resistance, and interpretation of the results in relation to phenotype could improve the performance of the system.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Ceftazidime / pharmacology
  • Humans
  • Imipenem / pharmacology
  • Microbial Sensitivity Tests / methods*
  • Phenotype
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Reagent Kits, Diagnostic*
  • Reproducibility of Results
  • beta-Lactam Resistance*
  • beta-Lactams / pharmacology

Substances

  • Anti-Bacterial Agents
  • Reagent Kits, Diagnostic
  • beta-Lactams
  • Imipenem
  • Ceftazidime